This Article Abstract Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bänsch, D. Articles by Block, M. Search for Related Content PubMed PubMed Citation Articles by Bänsch, D. Articles by Block, M.

CLINICAL STUDIES

Ventricular tachycardias above the initially programmed tachycardia detection interval in patients with implantable cardioverter-defibrillators

Incidence, prediction and significance

Dietmar Bänsch, MD, Marco Castrucci, MD^*, Dirk Böcker, MD^*, G.ünter Breithardt, MD, FACC, FESC^* and Michael Block, MD

^* Department of Cardiology/Angiology and Institute for Research in Arteriosclerosis, Westfälische Wilhelms-University, Münster, Germany
Department of Cardiology, Allgemeines Krankenhaus St. Georg, Hamburg, Germany
Department of Cardiology, Krankenhaus Augustinum, München, Germany

Manuscript received May 4, 1999; revised manuscript received January 20, 2000, accepted March 29, 2000.

Reprint requests and correspondence: Dr. Dietmar Bänsch, Department of Internal Medicine II, Cardiology, Allgemeines Krankenhaus St. Georg, Lohmühlenstr. 5, 20099 Hamburg, Germany
Bae151162{at}aol.com

	Abstract

Top Abstract Methods Results Discussion References

 
OBJECTIVES

This retrospective study was performed to provide data on ventricular tachycardias (VT) with a cycle length longer than the initially programmed tachycardia detection interval (TDI) in patients with implantable cardioverter defibrillators (ICDs).

BACKGROUND

It has been clinical practice to program a safety margin of 30 to 60 ms between the slowest spontaneous or inducible VT and the TDI.

METHODS

Baseline characteristics of 659 consecutive patients with ICDs were prospectively; follow-up information was retrospectively collected.

RESULTS

During a mean follow-up of 31 ± 23 months, 377 patients (57.2%) had at least one recurrent VT or ventricular fibrillation; 47 patients (7.1%) suffered 61 VTs above the TDI. The risk of a VT above the TDI ranged between 2.7% and 3.5% per year during the first four years after ICD implantation. The difference between the cycle length of the slowest VT before ICD implantation, spontaneous or induced, and the first VT above TDI was 108 ± 58 ms. Fifty-four VTs (88.5%) above the TDI were associated with significant clinical symptoms (angina or palpitation 63.9%, heart failure 6.6% and syncope 8.2%). Six patients (9.8%) had to be resuscitated. Kaplan-Meyer analysis identified New York Heart Association class II or III (p = 0.021), ejection fraction < 0.40 (p = 0.027), spontaneous (p < 0.001) or inducible (p < 0.001) monomorphic VTs and the use of class III antiarrhythmic drugs (amiodarone, p < 0.001; sotalol, p = 0.004) as risk predictors of VTs above the TDI. The risk of recurrent VTs above TDI was 11.8%, 12.5% and 26.6% during the first, second and third year after first VT above TDI, respectively.

CONCLUSIONS

The risk of VTs above the TDI is significantly increased in some patients, and many VTs above TDI cause significant clinical symptoms. A larger safety margin between spontaneous or inducible VTs and the TDI seems to be necessary in selected patients. This is in conflict with an increased risk of inadequate episodes and demands highly specific and sensitive detection algorithms in these patients.

Abbreviations and Acronyms   CL = cycle length   ECG = electrocardiogram   EF = ejection fraction   ICD = implantable cardioverter defibrillator   NYHA = New York Heart Association   PVS = programmed ventricular stimulation   TDI = tachycardia detection interval   VF = ventricular fibrillation   VT = ventricular tachycardia

The specificity of detection has been enhanced by additional criteria such as stability and onset of VT cycle length (CL) (9,10), QRS width of sensed electrograms (11) and in case of dual-chamber ICDs, atrioventricular dissociation (12–14). Nondetection of VTs or therapy delay, due to undersensing or algorithms that increase specificity of VT detection, has been described (8,9,15,16). In contrast, only single cases of VTs above the initially programmed TDI have been reported (17), and the incidence and clinical significance of these VTs remain to be defined.

In this study, the occurrence of VTs above TDI and their clinical impact was retrospectively analyzed in order to evaluate current programming practice and modify it, if necessary.

	Methods

Top Abstract Methods Results Discussion References

 
Definitions.   The occurrence of a VT, detected by the ICD, was assumed, if stored tachycardia CLs were short (<250 ms), or decreased suddenly at the onset of the tachycardia and were stable, or the morphology of stored electrograms was different from the morphology during sinus rhythm or antitachycardia pacing successfully terminated the tachyarrhythmias.

A VT above TDI was assumed, if at least a one-lead electrocardiogram (ECG) documentation of the VT was available. Nonsustained VTs above the TDI were not included. Few VTs (9 of 61) above TDI were gathered from ICD memory data. In these cases, the VT was symptomatic and lasted long enough for the patient to be hospitalized because of the VT, but the VT accelerated before an external ECG documentation could be obtained. All ECGs of VTs above TDI were reviewed by at least two cardiologists. If there was doubt about the origin of the tachycardia, it was not classified as ventricular.

ICD programming.   Programming practice has changed during the last decade due to technical and scientific progress. Coherence in programming strategy was achieved in our clinic by programming rules layed down in an ICD handbook, which the implanting physician had to follow.

We have always considered the spontaneous or inducible VT for ICD programming and added a safety margin between 30 and 60 ms to the slowest sustained VT. In case no VT was documented or induced, the programming strategy has changed during recent years. Until 1994, we used a one-zone shock-only programming in these patients, if anamnestic details such as syncope did not suggest monomorphic VTs. The TDI was programmed empirically between 180 and 220 beats/min depending on the patient’s left ventricular ejection fraction (EF). In recent years, we have always programmed two zones with a VT zone starting at 170 to 190 beats/min and a VF zone between 200 and 220 beats/min if no VT was documented, because several trials suggest that patients with structural heart disease tend to have VF initiated by VTs, even if no VTs could be documented (18).

Patients.   Baseline characteristics of 659 consecutive patients who received ICDs at our Institution (University of Münster) between July 1988 and August 1998 were prospectively collected in an ICD database. Indications for ICD implantation were survived cardiac arrest or polymorphic VT in 273 patients (41.4%), monomorphic VT in 188 (28.5%), monomorphic VT and VF in 141 (21.4%), nonsustained VT in 24 (3.6%) and syncope plus inducible VTs in 34 (5.2%; Table 1). Prophylactic indications for ICD implantation were excluded from analysis.

Variables for risk prediction of VTs, shocks and VTs below the detection rate were prospectively collected in an ICD database and included patients’ characteristics such as heart disease, New York Heart Association (NYHA) class at the time of implantation, history of decompensation, previous antiarrhythmic interventions, results of left and right heart catheter, spontaneous VTs, results of PVS, baseline electrocardiograms at implantation as well as hospital discharge data and antiarrhythmic medication at discharge and during follow-up.

Follow-up.   Patients visited the ICD outpatient clinic routinely every three months and were encouraged to schedule additional visits, if the first shock, clusters of shocks or syncope occurred. They were questioned about extraordinary events such as extra hospital admissions for cardiac events, and medical reports of these events were obtained. If patients died, we routinely performed a postmortem interrogation of the device. No patient has been lost to follow-up. However, patients who were no longer followed at our or an affiliated clinic and patients who underwent ICD explantation for various reasons were censored at the last visit at our or an affiliated clinic. Chart reviews and printouts were checked for VTs above the programmed TDI, causes or permissive factors and measures taken to avoid recurrences. Mean follow-up time was 31 ± 26 months.

Statistical analysis.   Mean ± standard deviation was used for continuous variables with normal distribution and t test was applied to compare means. Median and range or 95% confidence interval was used to describe continuous variables without normal distribution and Mann Whitney U test was applied to compare ranks. Frequency distributions between groups of patients were tested with the chi square test. A two-tailed p value of equal or less than 0.05 was regarded as significant. The probability of major events was calculated according to the Kaplan-Meier method and measured from the date of implantation, first VT or first VT above TDI to the event (20). Differences between pairs of actuarial curves were tested by Mantel-Haenszel log-rank test. Cox regression analysis was performed on patients’ baseline characteristics to investigate the influence of different variables. For continuous variables, the hazard for an increase of one in the value of the covariate was calculated from the regression coefficient b: exp(b). For binary variables, the hazard ratio for the presence of a certain characteristic was calculated as exp(b), where b is the regression coefficient. Statistical analysis was done with SPSS (Statistical Package for Social Sciences, version 6.0) for Windows.

	Results

Top Abstract Methods Results Discussion References

 
Incidence of tachycardias below the detection rate.   Patients’ baseline characteristics are presented in Table 1. Three hundred seventy-seven patients (57.2%) had a recurrent VT or VF. The per-year risk to suffer a first VT decreased during the first four years and was 59.2%, 23.9%, 13.7% and 8.3% in the first, second, third and fourth year after ICD implantation, respectively. Forty-seven patients (7.1%) suffered 61 VTs below the detection rate. Forty-eight VTs above TDI (78.8%) were documented with 12-channel ECGs, four (6.6%) during holter monitoring and nine (14.8%) could be gathered from ICD memory data. In these patients, tachycardia lasted long enough that hospital admission was initiated, but the VTs accelerated into the programmed detection zone before an ECG could be obtained. The CLs of VTs above TDI were 441 ± 60 ms. The difference between the VT above TDI and the slowest VT, spontaneous or induced, before ICD implantation was 108 ± 58 ms. The difference between the initially programmed TDI and the first VT above TDI was 39 ± 34 ms.

The risk of a VT above TDI was about 3% (range 2.7% to 3.5% per year) and remained fairly constant during the first four years after ICD implantation (Table 2, Fig. 1). The relative risk for a first VT being a VT above TDI, therefore, increased with time (see risk of any first VT), and was 5.1%, 11.3%, 25.5% and 32.5% during the first, second, third and fourth year after ICD implantation in 281, 62, 20 and 12 patients with first VTs, respectively.

View larger version (23K): [in this window] [in a new window]   Figure 1 Risk of VTs above the programmed tachycardia detection interval.

The risk of VTs above TDI ranged between 4.6% and 5.9% per year during the first four years in patients with spontaneous monomorphic VTs, in contrast to 0.9% to 1.4% in patients without monomorphic VTs (Table 2; Fig. 2). Patients without inducible monomorphic VTs, patients with inducible VF and polymorphic VTs included, had a significantly lower risk to suffer a VT above TDI during the first four years (0% to 1.3% per year during the first four years) than patients with inducible monomorphic VTs (3.7% to 5.3% per year, p < 0.001; Table 2, Fig. 3).

View larger version (21K): [in this window] [in a new window]   Figure 2 Risk of VTs above the programmed tachycardia detection interval and spontaneous ventricular tachycardias before ICD implantation. pres. mVT = presenting monomorphic ventricular tachycardia.

View larger version (30K): [in this window] [in a new window]   Figure 3 Risk of VTs above the programmed tachycardia detection interval and inducible tachycardias. ind. MVT = inducible monomorphic VT; VF = ventricular fibrillation; VT = ventricular tachycardia.

The risk of experiencing a VT above TDI was most prominently related to the use of class III antiarrhythmic drugs. Although all patients underwent PVS after any change in antiarrhythmic medication and ICDs were programmed according to the results (in the case of amiodarone PVS was performed after a loading phase), the risk of a VT above TDI was 25% during the first year in patients on amiodarone (p < 0.001 in comparison with patients without antiarrhythmic drugs), and ranged between 4.7% and 11.1% per year during the first four years after prescription of either d- or d,l-sotalol (p = 0.004 in comparison with patients on no antiarrhythmic drugs (Table 2; Fig. 4).

View larger version (20K): [in this window] [in a new window]   Figure 4 Risk of VTs above the initially programmed tachycardia detection interval and presence of risk predictors (inducible monomorphic VTs, NYHA class II + III, amiodarone).

Clinical significance.   Only 7 VTs above TDI were asymptomatic and were detected by chance in routine ECGs or Holter ECGs during follow-up visits; 54 (88.5%) caused clinical symptoms and admission to the hospital, 39 (63.9%) caused palpitations or angina, 4 (6.6%) were associated with cardiac decompensation, 5 (8.2%) caused syncope and during 6 VTs (9.8%) above TDI patients had to be resuscitated.

Ventricular tachycardias above TDI that caused no symptoms and palpitation or angina were similar in CL (447 ± 46.8 ms, range 400 to 520 ms, vs. 445 ± 61 ms, range 330 to 550 ms). Ventricular tachycardias that were associated with cardiac decompensation (CL 505 ± 72 ms, range 330 to 550 ms) tended to be slower (NS). Ventricular tachycardias that caused syncope (358 ± 48 ms, range 340 to 460 ms) or cardiopulmonary resuscitation (CL 407 ± 36 ms, range 350 to 450 ms) tended to be faster than asymptomatic VTs (NS). All but one patient were successfully resuscitated, however, four died within one week of resuscitation, three of end-stage heart failure and one with intractable incessant VT.

Sixteen VTs above TDI (26.2%) terminated spontaneously, and nine VTs accelerated into the programmed detection zone on hospital admission and thus required no additional intervention. Thirty-six VTs above TDI required external intervention: in 14 cases (23%), the detection rate was decreased and the ICD terminated the VT automatically, in two cases (3.3%), VTs were terminated with manual overdrive stimulation via the ICD, 9 VTs (14.8%) were terminated with intravenous antiarrhythmic drugs and 11 (18%) with external overdrive stimulation after intracardiac placement of a stimulation catheter or external emergency cardioversion.

Intervention to prevent recurrence.   After all but three VTs were above the TDI, the TDI was adjusted using a safety margin of at least 30 ms. In three patients, the TDI was not increased adequately, because the VT CL ranged between 500 and 600 ms and was well tolerated (n = 2) or this VT was successfully treated with radiofrequency ablation (n = 1). In one patient without inducible or documented VTs before ICD implantation, a one-zone shock-only device had to be replaced by a multi-zone device to allow for antitachycardia pacing.

Despite an adjusted TDI, 9 of 47 patients had at least one recurrent VT above TDI, 3 patients had at least two and 2 patients had three recurrences. The risk of recurrent VTs above TDI was 11.8% during the first, 12.5% during the second and 26.6% during the third year after first VT above TDI. In all cases, a further increase in VT CL caused the second VT above TDI. The CL of the first VT above TDI was 424 ± 52 ms and the CL of the second VT was 487 ± 39 ms (p < 0.002).

If we had intended to address any VT of 50% of patients with slow VTs, TDI would have to be increased to 25 to 27 ms, for 80%, TDI would have to be increased to 50 ms and for 90%, by 90 to 100 ms.

	Discussion

Top Abstract Methods Results Discussion References

 
In this large cohort of patients with ICDs, the risk of a VT above TDI ranged between 2.7% and 3.5% per year and remained constant over time. Impaired left ventricular function, inducible and spontaneous monomorphic VTs and class III antiarrhythmic drugs, especially amiodarone, could be identified as independent risk predictors of a VT above the initially programmed TDI. The first two risk predictors also predicted any recurrent VT.

The occurrence of VTs above the TDI may be explained in two ways. First, we may have documented the far end of a distribution curve of spontaneous VT CLs, i.e., the 97th percentile. The fact that the risk of a VT above the TDI remained constant over time favors this "sampling error" explanation. Second, a significant slowing of VTs occurs over time with the use of class III antiarrhythmic drugs in the setting of a high recurrence risk of VTs. If the occurrence of VTs above the TDI was a matter of chance, the probability of a recurrent VT above TDI should be less than that of the initial VT, if the TDI was increased. However, the risk of a recurrent VT increased to 0.12 per year in spite of an increase in TDI. This favors the view that at least in some patients a significant slowing of VTs occurred. A look at individual patients with VTs above the TDI revealed that in each case the VT above the TDI was much slower than any VT spontaneous or induced earlier. And the recurrent VT above the TDI was again slower than the first in almost all cases (424 ± 52 vs. 487 ± 39 ms, p < 0.002).

Patients without risk predictors.   The risk of VTs above TDI in patients after survived cardiac arrest without spontaneous or inducible monomorphic VTs and preserved left ventricular function was below 1% per annum. Thus, the current practice to program a TDI of 280 to 330 ms for the detection interval in these patients seems to be adequate. The risk of a monomorphic VT during follow-up has been reported to be 18% in these patients during a follow-up of 14 months (18). This favors a two-zone device with the possibility of antitachycardia pacing even in patients without documented VTs.

Patients with risk predictors of VTs above the TDI.   Patients with single risk predictors presented with a 5% risk to have a VT above the TDI during the first two years. This risk is almost tripled in patients with all three risk predictors and reaches 30% after four years.

The risk of a VT above TDI was significantly increased in patients with spontaneous (4.6% to 5.9% per year) or inducible (3.7% to 5.3% per year) monomorphic VTs. This finding was most surprising because we expected that in patients in whom we had information about spontaneous tachycardias, the actual risk should have been lower. Of interest, those patients with VTs above TDI did show a trend to slower VTs during predischarge PVS. The opposite was true for patients with VTs below the TDI.

VTs above TDI and heart failure.   Most VTs above TDI caused clinical symptoms and hospital admission (88.5%); 24.6% of VTs above TDI were even associated with devastating events such as heart failure, syncope or cardiopulmonary resuscitation.

The association between cardiac decompensation and slowing of VTs may first be explained by a progressive scarring of the myocardium, which again may cause slowing of conduction (21–23).

Second, slow VTs caused cardiac arrest and heart failure in some patients, although VTs were very slow (407 ms for cardiac arrest, 505 ms for heart failure), because patients with impaired left ventricular function often do not feel any palpitations and VTs are not documented until these patients are hospitalized for other symptoms such as angina and heart failure. The fact that heart failure was reversible in all but three patients favors this view.

Antiarrhythmic medication.   Although all patients underwent PVS in our clinic, if antiarrhythmic therapy was changed (in case of amiodarone after a loading phase), to detect an increase in defibrillation threshold and a slowing of VTs above the TDI, the risk of VTs above the TDI was significantly increased on amiodarone (25% during the first year after initiation of therapy) or sotalol (4.7% to 11.1% per year during the first four years) (24). This suggests an increase of TDI after the initiation of antiarrythmic therapy irrespective of EPS results.

Furthermore, the initiation of antiarryhthmic therapy should be restricted to otherwise untractable patients with many episodes that require shocks, because we may just replace the problem of frequent tachycardias with the problem of VTs above the TDI with significant clinical impact. With the favorable results of radiofrequency ablation both in patients with coronary artery disease, reported by Strickberger et al. (25) and in patients with dilated cardiomyopathy, reported by Kottkamp et al. (22), radiofrequency ablation should always be considered first line therapy.

Which TDI for which patient.   Only 50% of the VTs below the detection rate could have been detected if the detection interval had been increased by 25 ms beyond the usual 30 to 60 ms (7). Ninety percent detection would have required an increase in detection interval by 87 ms, and a 95% detection would have made an increase of the TDI by 123 ms necessary. The need for a much larger safety margin in some patients is in conflict with the fact that an increase in TDI is strongly associated with inappropriate episodes. Our report on the same cohort, published elsewere, revealed that an increase of TDI by 10 beats/min increased the risk of inappropriate episodes by 20% (26).

The clinical effects of the VTs above the TDI may suggest an increase in TDI in patients who are prone to highly symptomatic slow VTs. However, it is not yet clear whether such slow VTs can be addressed by ICD therapy at all with an acceptable risk of inadequate therapies and whether this translates into a survival benefit.

Another solution to the dilemma between a mandatory decrease of detection rate in patients with presenting or inducible monomorphic VTs or on antiarrhythmic therapy and the increasing risk of inappropriate episodes may be detection algorithms, which allow for more independence from detection rate. Such algorithms may include atrioventricular dissociation (12–14) or QRS width (10,11) as first-line detection criterion, especially in patients prone to very slow VTs.

Conclusions and outlook.   If the TDI of an ICD is programmed as the CL of the slowest spontaneous or inducible VT plus 30 to 60 ms, the risk of a VT below the detection rate was about 3% per year. The risk of a recurrent VT above the TDI ranged between 11% and 13% per year during the first two years after the first VT above the TDI, although the TDI was adapted to the slow VT.

The clinical effects of VTs above the TDI may suggests an increase in TDI in selected patients. However, an increase in TDI increases the risk of inappropriate therapies. The questions whether slow VTs should be addressed by ICDs at all and whether this is feasible with current ICD technology have to be answered by a prospective trial, which is underway: the "1+1–Trial."

Study limitations.   A retrospective analysis of VTs above TDI is naturally based on reports of clinical emergencies. Therefore, the number of VTs and the risk of VTs above TDI may have been underestimated. Additionally, some sudden deaths despite ICDs might be due to VTs above TDI, as some of our patients with VTs above TDI had to be resuscitated. Grubman et al. (27) reported that in 46% of patients dying suddenly despite ICDs, no VT had been recorded.

Supraventricular tachycardias with bundle-branch-block morphology may have been erroneously taken for VTs. However, ECGs were reviewed with care by at least two cardiologists. If there were doubts about the ventricular origin of the tachyarrhythmia, the episode was not supposed to be of ventricular origin. Furthermore, atrial fibrillation and sinus tachycardias during treadmill ECG, which we have reported to be the strongest predictors and major causes of inappropriate episodes, were not predictors of an increased risk of VTs above TDI (Table 1). Therefore, we assume that differentiation of VTs from other kinds of episodes was sufficiently achieved (24).

Finally, all generations of ICDs were included in the study. With current programming options, the detection rate may be programmed less restrictively and the risk of VTs above the TDI may be lower.

	References

Top Abstract Methods Results Discussion References

 
1. Mirowski M, Reid PR, Mower MM, Watkins L, Gott V, Schauble JF. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings. N Engl J Med. 1980;303:322–324[Medline]

2. Bocker D, Block M, Isbruch F, et al. Do patients with an implantable defibrillator live longer? J Am Coll Cardiol. 1993;21:1638–1644[Abstract]

3. Bocker D, Block M, Isbruch F, et al. Benefits of treatment with implantable cardioverter-defibrillators in patients with stable ventricular tachycardia without cardiac arrest. Br Heart J. 1995;73:52–63

4. Block M, Breithardt G. Long-term follow-up and clinical results of implantable cardioverter defibrillators. Zipes DP, Jalife J. Cardiac Electrophysiology: From Cell to Bedside. Philadelphia: WB Saunders; 1995. p. 1412–1425

5. Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implantable defibrillator in patients with coronary artery disease at high risk of ventricular arrhythmia. N Engl J Med. 1996;335:1933–1940[Abstract/Free Full Text]

6. AVID Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med. 1997;337:1576–1583[Abstract/Free Full Text]

7. Zaim BR, Zaim SH, Rankin AC, McGovern BA, Garan H, Ruskin JN. Comparison of cycle lengths between induced and spontaneous sustained ventricular tachycardia during concordant antiarrhythmic therapy associated with healed myocardial infarction. Am J Cardiol. 1996;77:2–4

8. Schaumann A, von zur Muhlen F, Herse B, Gonska B. Empirical versus tested antitachycardia pacing in implantable cardioverter defibrillators. Circulation. 1998;97:66–74[Abstract/Free Full Text]

9. Swerdlow CD, Ahern T, Chen PS, et al. Underdetection of ventricular tachycardia by algorithms to enhance specificity in a tiered-therapy cardioverter-defibrillator. J Am Coll Cardiol. 1994;24:416–424[Abstract]

10. Swerdlow CD, Chen PS, Kass RM, Allard JR, Peter CT. Discrimination of ventricular tachycardia from sinus tachycardia and atrial fibrillation in a tiered-therapy cardioverter-defibrillator. J Am Coll Cardiol. 1994;23:1342–1355[Abstract]

11. Jazayeri MR, Sra JJ, Akhtar M. Wide QRS complexes: electrophysiologic basis of a common electrocardiographic diagnosis. J Cardiovasc Electrophysiol. 1992;3:365–393

12. Schuger CD, Jackson K, Steinman RT, Lehmann MH. Atrial sensing to augment ventricular tachycardia detection by the automatic implantable cardioverter defibrillator: a utility study. PACE. 1988;11:1456–1464

13. Korte T, Jung W, Wolpert C, et al. A new classification algorithm for discrimination of ventricular from supraventricular tachycardia in a dual chamber implantable cardioverter defibrillator. J Cardiovasc Electrophysiol. 1998;9:70–73[Medline]

14. Nair M, Saoudi N, Kroiss D, Letac B. Automatic arrhythmia identification using analysis of the atrioventricular association: application to a new generation of implantable defibrillators. Circulation. 1997;95:967–973[Abstract/Free Full Text]

15. Le FP, Kus T, Vinet A, Rocque P, Molin F, Costi P. Underdetection of ventricular tachycardia using a 40 ms stability criterion: effect of antiarrhythmic therapy. PACE. 1997;20:2882–2892

16. Michelson BI, Igel DA, Wilkoff BL. Adequacy of implantable cardioverter-defibrillator lead placement for tachyarrhythmia detection by sinus rhythm electrogram amplitude. Am J Cardiol. 1995;76:1162–1166[CrossRef][Medline]

17. Ziwen R, Jun Z, Youcheng S. Clinical application of the fourth generation implantable cardioverter-defibrillator. Chin J Cardiol. 1997;25:120–123

18. Raitt MH, Dolack GL, Kudenchuk PJ, Poole JE, Bardy GH. Ventricular arrhythmias detected after transvenous defibrillator implantation in patients with a clinical history of only ventricular fibrillation. Implications for use of implantable defibrillator. Circulation. 1995;91:1996–2001[Abstract/Free Full Text]

19. Borggrefe M, Trampisch HJ, Breithardt G. Reappraisal of criteria for assessing drug efficacy in patients with ventricular tachyarrhythmias: complete versus partial suppression of inducible arrhythmias. J Am Coll Cardiol. 1988;12:140–149[Abstract]

20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;:457–481

21. Mary-Rabine L, Albert A, Pham TD, et al. The relationship of human cellular electrophysiology to clinical function and ultrastructure. Circ Res. 1983;52:188–199[Abstract/Free Full Text]

22. Kottkamp H, Hindricks G, Chen X, et al. Radiofrequency catheter ablation of sustained ventricular tachycardia in idiopathic dilated cardiomyopathy. Circulation. 1995;92:1159–1168[Abstract/Free Full Text]

23. Kolettis TM, Theodorakis GN, Livanis E, Zarvalis E, Paraskevaidis I, Kremastinos DT. Incessant ventricular tachycardia associated with congestive heart failure. PACE. 1995;18:2096–2099

24. Brunn J, Block M, Weber M, et al. Results of testing defibrillator function of implanted cardioverter/defibrillators. Z Kardiol. 1997;86:450–458[CrossRef][Medline]

25. Strickberger SA, Man KC, Daoud EG, et al. A prospective evaluation of catheter ablation of ventricular tachycardia as adjuvant therapy in patients with coronary artery disease and an implantable cardioverter defibrillator. Circulation. 1997;96:1525–1531[Abstract/Free Full Text]

26. Weber M, Block M, Brunn J, et al. [Inadequate therapies with implantable cardioverter-defibrillators]. Z Kardiol 1996;85:809–19.

27. Grubman EM, Pavri BB, Shipman T, Britton N, Kocovic DZ. Cardiac death and stored electrograms in patients with third-generation implantable cardioverter-defibrillators. J Am Coll Cardiol. 1998;32:1056–1062[Abstract/Free Full Text]

This article has been cited by other articles:

				B. L. Wilkoff, B. D. Williamson, R. S. Stern, S. L. Moore, F. Lu, S. W. Lee, U. M. Birgersdotter-Green, M. S. Wathen, I. C. Van Gelder, B. M. Heubner, et al. Strategic Programming of Detection and Therapy Parameters in Implantable Cardioverter-Defibrillators Reduces Shocks in Primary Prevention Patients: Results From the PREPARE (Primary Prevention Parameters Evaluation) Study J. Am. Coll. Cardiol., August 12, 2008; 52(7): 541 - 550. [Abstract] [Full Text] [PDF]

				G. Boriani, E. Occhetta, S. Cesario, S. Grossi, M. Marconi, G. Speca, P. Silvestri, M. Biffi, M. Bortnik, C. Martignani, et al. Contribution of morphology discrimination algorithm for improving rhythm discrimination in slow and fast ventricular tachycardia zones in dual-chamber implantable cardioverter-defibrillators Europace, August 1, 2008; 10(8): 918 - 925. [Abstract] [Full Text] [PDF]

				D. Bansch, H. Kottkamp, G. Gronefeld, J. Vogt, C. Israel, D. Bocker, G. Hindricks, K.-H. Kuck, and on behalf of the Quick-ICD investigators The quick-implantable-defibrillator trial Europace, December 1, 2007; 9(12): 1144 - 1150. [Abstract] [Full Text] [PDF]

				J. Almendral and M. E. Josephson All Patients With Hemodynamically Tolerated Postinfarction Ventricular Tachycardia Do Not Require an Implantable Cardioverter-Defibrillator Circulation, September 4, 2007; 116(10): 1204 - 1212. [Full Text] [PDF]

				B. L. Wilkoff, K. T. Ousdigian, L. D. Sterns, Z. J. Wang, R. D. Wilson, J. M. Morgan, and for the EMPIRIC Trial Investigators A Comparison of Empiric to Physician-Tailored Programming of Implantable Cardioverter-Defibrillators: Results From the Prospective Randomized Multicenter EMPIRIC Trial J. Am. Coll. Cardiol., July 18, 2006; 48(2): 330 - 339. [Abstract] [Full Text] [PDF]

				N. Sadoul, R. Mletzko, F. Anselme, R. Bowes, W. Schols, C. Kouakam, G. Casteigneau, R. Luise, N. Iscolo, E. Aliot, et al. Incidence and Clinical Relevance of Slow Ventricular Tachycardia in Implantable Cardioverter-Defibrillator Recipients: An International Multicenter Prospective Study Circulation, August 16, 2005; 112(7): 946 - 953. [Abstract] [Full Text] [PDF]

				M. O. Sweeney, M. S. Wathen, K. Volosin, I. Abdalla, P. J. DeGroot, M. F. Otterness, and A. J. Stark Appropriate and Inappropriate Ventricular Therapies, Quality of Life, and Mortality Among Primary and Secondary Prevention Implantable Cardioverter Defibrillator Patients: Results From the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) Trial Circulation, June 7, 2005; 111(22): 2898 - 2905. [Abstract] [Full Text] [PDF]

				D. Bansch, F. Steffgen, G. Gronefeld, C. Wolpert, D. Bocker, R.-U. Mletzko, W. Schols, K. Seidl, M. Piel, F. Ouyang, et al. The 1+1 Trial: A Prospective Trial of a Dual- Versus a Single-Chamber Implantable Defibrillator in Patients With Slow Ventricular Tachycardias Circulation, August 31, 2004; 110(9): 1022 - 1029. [Abstract] [Full Text] [PDF]

				A. E. Buxton The Clinical Use of Implantable Cardioverter Defibrillators: Where Are We Now? Where Should We Go? Ann Intern Med, March 18, 2003; 138(6): 512 - 514. [Full Text] [PDF]

				A. E. Buxton, K. L. Lee, G. E. Hafley, D. G. Wyse, J. D. Fisher, M. H. Lehmann, L. A. Pires, M. R. Gold, D. L. Packer, M. E. Josephson, et al. Relation of Ejection Fraction and Inducible Ventricular Tachycardia to Mode of Death in Patients With Coronary Artery Disease: An Analysis of Patients Enrolled in the Multicenter Unsustained Tachycardia Trial Circulation, November 5, 2002; 106(19): 2466 - 2472. [Abstract] [Full Text] [PDF]

				D. Bansch, M. Antz, S. Boczor, M. Volkmer, J. Tebbenjohanns, K. Seidl, M. Block, F. Gietzen, J. Berger, and K. H. Kuck Primary Prevention of Sudden Cardiac Death in Idiopathic Dilated Cardiomyopathy: The Cardiomyopathy Trial (CAT) Circulation, March 26, 2002; 105(12): 1453 - 1458. [Abstract] [Full Text] [PDF]

This Article Abstract Figures Only Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bänsch, D. Articles by Block, M. Search for Related Content PubMed PubMed Citation Articles by Bänsch, D. Articles by Block, M.